Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 7:36 PM
Ignite Modification Date:
2025-12-24 @ 7:36 PM
NCT ID:
NCT02164903
Eligibility Criteria:
Inclusion Criteria:
* 18 years or older at the time of study entry;
* Diagnosis of Philadelphia chromosome positive and/or BCR-ABL positive CML confirmed by cytogenetic and/or molecular analysis;
* At least in CCyR (as documented by chromosome banding analysis of marrow cell metaphases) or in MMR (≤0.1% BCR-ABL IS)
* CP-CML Patients in first line treatment with either dasatinib or imatinib for no more than 3 years;
* Written informed consent.
Exclusion Criteria:
* Major cognitive deficits or psychiatric problems hampering a self-reported evaluation.
* Not speaking and reading the language of the participating country.
* Having received any CML treatment prior to therapy with imatinib or dasatinib for more than three months.
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT02164903
Study Brief:
Protocol Section:
NCT02164903